Tweet
Ascension Asset Management LLC boosted its position in ResMed Inc. (NYSE:RMD) by 4.0% during the second quarter, HoldingsChannel.com reports. The fund owned 17,100 shares of the medical equipment provider's stock after buying an additional 650 shares during the quarter. ResMed comprises 1.6% of Ascension Asset Management LLC's holdings, making the stock its 26th biggest position. Ascension Asset Management LLC's holdings in ResMed were worth $1,771,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Hudson Valley Investment Advisors Inc. ADV raised its stake in ResMed by 2.2% in the 2nd quarter. Hudson Valley Investment Advisors Inc. ADV now owns 60,974 shares of the medical equipment provider's stock valued at $6,316,000 after acquiring an additional 1,301 shares during the period. Dupont Capital Management Corp purchased a new position in ResMed during the 1st quarter valued at about $121,000. Achmea Investment Management B.V. grew its holdings in ResMed by 157.9% during the 2nd quarter. Achmea Investment Management B.V. now owns 34,689 shares of the medical equipment provider's stock valued at $3,591,000 after buying an additional 21,241 shares in the last quarter. Norinchukin Bank The grew its holdings in ResMed by 18.3% during the 1st quarter. Norinchukin Bank The now owns 14,117 shares of the medical equipment provider's stock valued at $1,390,000 after buying an additional 2,182 shares in the last quarter. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in ResMed by 19.3% during the 1st quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 87,733 shares of the medical equipment provider's stock valued at $8,639,000 after buying an additional 14,209 shares in the last quarter. Institutional investors and hedge funds own 62.68% of the company's stock. Get ResMed alerts:
In other news, Director Richard Sulpizio sold 28,403 shares of the business's stock in a transaction dated Wednesday, May 30th. The stock was sold at an average price of $102.78, for a total transaction of $2,919,260.34. Following the completion of the transaction, the director now owns 35,823 shares of the company's stock, valued at $3,681,887.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, CFO Brett Sandercock sold 2,000 shares of the business's stock in a transaction dated Friday, June 15th. The stock was sold at an average price of $106.76, for a total value of $213,520.00. Following the transaction, the chief financial officer now directly owns 67,072 shares of the company's stock, valued at approximately $7,160,606.72. The disclosure for this sale can be found here . Insiders have sold 41,823 shares of company stock valued at $4,342,578 in the last three months. 1.77% of the stock is owned by insiders. RMD stock opened at $106.84 on Friday. The company has a quick ratio of 1.56, a current ratio of 2.08 and a debt-to-equity ratio of 0.13. The stock has a market cap of $15.38 billion, a price-to-earnings ratio of 30.27, a P/E/G ratio of 2.78 and a beta of 0.89. ResMed Inc. has a twelve month low of $72.49 and a twelve month high of $109.97.
ResMed (NYSE:RMD) last posted its earnings results on Thursday, August 2nd. The medical equipment provider reported $0.95 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.95. The business had revenue of $623.63 million during the quarter, compared to analyst estimates of $622.78 million. ResMed had a return on equity of 24.74% and a net margin of 13.49%. The company's quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.77 EPS. sell-side analysts expect that ResMed Inc. will post 3.66 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 20th. Stockholders of record on Thursday, August 16th will be issued a dividend of $0.37 per share. This is a positive change from ResMed's previous quarterly dividend of $0.35. The ex-dividend date of this dividend is Wednesday, August 15th. This represents a $1.48 annualized dividend and a dividend yield of 1.39%. ResMed's payout ratio is presently 39.66%.
A number of research analysts have weighed in on the company. Zacks Investment Research raised ResMed from a "sell" rating to a "hold" rating in a report on Tuesday, July 31st. UBS Group lowered ResMed from a "buy" rating to a "neutral" rating in a report on Tuesday, April 24th. Finally, Goldman Sachs Group assumed coverage on ResMed in a report on Sunday, July 1st. They set a "buy" rating for the company. Three analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. ResMed has an average rating of "Hold" and an average price target of $77.33.
About ResMed
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Featured Article: What is a Leveraged Buyout (LBO)?
Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD). Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter 